Full Year 2024 CSL Ltd Earnings Call Transcript
Key Points
- CSL Ltd (CMXHF) reported strong revenue growth of 11% at constant currency, reaching $14.8 billion.
- Net profit after tax (NPAT) increased by 25%, amounting to $2.6 billion.
- The CSL Behring business unit delivered robust growth, with the Ig franchise growing by 20%.
- CSL Vifor achieved over $100 million in synergies post-acquisition, indicating successful integration.
- The company made significant progress on strategic priorities, including the rollout of Rika and FDA clearance for Terumo's individualized nomogram.
- CSL Vifor faced challenges with generic competition impacting FERINJECT sales.
- The transition from referrals to administrations for HEMGENIX in the US has been slower than anticipated.
- CSL Seqirus experienced modest revenue growth of 4%, below expectations.
- The company faced a 60-basis-point FX headwind impacting gross margins.
- The overall CapEx spend reduced by 31%, which may indicate potential limitations in future capacity expansion.
Good morning, everyone, and welcome to CSL's financial year 2024 results presentation. I'm Joy Linton, CSL's Chief Financial Officer.
And before we begin the formalities today, I would like to say a few words about Mark Dehring, who has opened today's calls over the past 21 years. As many of you know, Mark Dehring has decided to retire as the head of CSL's Investor Relations Function. Over his extensive time with us. He's been a trusted adviser to our leadership group and respected spokesperson with the investment community. In the time I've been at CSL, I've very much valued Mark's wisdom, guidance and insights. So thank you, Mark.
Also with us today having moved into Mark's role is Chris Cooper, who joined CSL earlier this year. Many of you will know Chris from his successful career as a healthcare analyst, and we are delighted to have him on our side of the fence. So Chris, welcome to your first CSL results announcement, and over to you.
Thank
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
